dolasetron has been researched along with quinuclidines in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (75.00) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Grunberg, SM; Koeller, JM | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Board, R; Board, T | 1 |
| Awab, A; Chaudhary, L; Hamadani, M; Tfayli, A | 1 |
| McNulty, R | 1 |
| Wilkes, G | 1 |
| Trepanier, L | 1 |
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Antony, J; Hemmelgarn, B; Hui, W; Hutton, B; Moher, D; Soobiah, C; Straus, SE; Struchkov, V; Tricco, AC | 1 |
6 review(s) available for dolasetron and quinuclidines
| Article | Year |
|---|---|
Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2003 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting.
Topics: Adult; Algorithms; Antiemetics; Child; Dexamethasone; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Evidence-Based Medicine; Granisetron; Humans; Indoles; Isoquinolines; Nurse's Role; Nursing Assessment; Ondansetron; Operating Room Nursing; Palonosetron; Patient Selection; Postoperative Nausea and Vomiting; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Risk Assessment; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists | 2006 |
Acute vomiting in cats: rational treatment selection.
Topics: Acute Disease; Animals; Antiemetics; Cat Diseases; Cats; Chlorpromazine; Diarrhea; Famotidine; Indoles; Metoclopramide; Nausea; Ondansetron; Prochlorperazine; Quinolizines; Quinuclidines; Ranitidine; Sucralfate; Vomiting; Weight Loss | 2010 |
Interventions to decrease the risk of adverse cardiac events for patients receiving chemotherapy and serotonin (5-HT3) receptor antagonists: a systematic review.
Topics: Antiemetics; Antineoplastic Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrocardiography; Humans; Indoles; Isoquinolines; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists | 2015 |
2 trial(s) available for dolasetron and quinuclidines
| Article | Year |
|---|---|
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
4 other study(ies) available for dolasetron and quinuclidines
| Article | Year |
|---|---|
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
Relative efficacy of ondansetron, granisetron, dolasetron and palonosetron in controlling acute nausea and vomiting associated with platinum-based chemotherapy.
Topics: Antiemetics; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Ondansetron; Organoplatinum Compounds; Palonosetron; Quinolizines; Quinuclidines; Treatment Outcome; Vomiting | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |